Published in Vaccine Weekly, January 19th, 2000
The patent is the ninth issued in the United States for which Antigenics has exclusive worldwide rights.
The company's lead product candidate for treatment of autoimmune diseases is the heat shock protein gp96, which has demonstrated efficacy in animal models of type 1 diabetes and multiple sclerosis. Antigenics has also made progress in elucidating the mechanism by which heat shock proteins modulate the immune system to treat these diseases.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.